We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Varenicline and Placebo for Smoking Cessation in Schizophrenia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00554840
First Posted: November 7, 2007
Last Update Posted: May 17, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Elaine Weiner, University of Maryland
  Purpose
The purpose of this proposed pilot study is to examine the use of varenicline in people with schizophrenia to specifically assess tolerability and efficacy for smoking cessation. Specifically, The primary objective of this pilot study is to determine if taking of varenicline along with an individual smoking cessation supportive program is a safe and effective treatment of nicotine addiction in schizophrenic patients. We hypothesize that the varenicline treated patients will achieve higher rates of smoking cessation than those who receive placebo and individual support.

Condition Intervention Phase
Cigarette Smoking Schizophrenia Drug: varenicline Drug: placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparison of Varenicline and Placebo for Smoking Cessation in Schizophrenia

Resource links provided by NLM:


Further study details as provided by Elaine Weiner, University of Maryland:

Primary Outcome Measures:
  • Change of ExpiredCO Level From Baseline [ Time Frame: Weekly for 12 weeks ]
    End expired carbon monoxide (CO) level change from baseline to determine participants' level of smoking reduction by treatment assignment. Larger negative values represent a greater level of smoking reduction.

  • Level of Nicotine Dependence by Treatment Assignment [ Time Frame: Weekly for 12 weeks ]
    Nicotine dependence was measured using the total score from the Fagerstrom Test for Nicotine Dependence (FTND) assessment. The total score is computed by adding the scores from the five subscales. Total scores range from 1-10, with lower scores representing a smaller degree of nicotine dependence.


Secondary Outcome Measures:
  • Brief Psychiatric Rating Scale (BPRS) - Total Score [ Time Frame: Baseline (week 0) then again during the Treatment Phase at weeks 1, 2, 4, 8, and 12. ]
    The total BPRS score is calculated by adding the scores for subscales #1-#18. Each scale ranges from "1=Not Present" to "7=Very Severe". Total scores range from a minimum score of 18 to a maximum score of 126. A higher total score indicates a more severe psychiatric symptom rating.

  • Brief Psychiatric Rating Scale (BPRS) - Psychosis Score [ Time Frame: Baseline (week 0) then again during the Treatment Phase at weeks 1, 2, 4, 8, and 12. ]
    The psychosis score is calculated by adding the scores for scales #4 Conceptual Disorganization, #11 Suspiciousness, #12 Hallucinatory Behavior, and #15 Unusual Thought Content. Each scale ranges from "1=Not Present" to "7=Very Severe". The minimum psychosis score is 4 and the maximum psychosis score is 28. A higher score indicates a more severe psychosis rating.

  • Brief Psychiatric Rating Scale (BPRS) - Anxiety/Depression Score [ Time Frame: Baseline (week 0) then again during the Treatment Phase at weeks 1, 2, 4, 8, and 12. ]
    The anxiety/depression score is calculated by adding the scores for scales #2 Anxiety and #9 Depressive Mood. Each scale ranges from "1=Not Present" to "7=Very Severe". The minimum anxiety/depression score is 2 and the maximum psychosis score is 14. A higher score indicates a more severe anxiety/depression rating.

  • Side Effects [ Time Frame: Weekly for 12 weeks ]
    Side effects (33 items) were measured using a Side Effects Checklist (SEC). The percentage of participants endorsing each side effect were reported regardless of the severity or relation to study drug.


Enrollment: 16
Study Start Date: November 2007
Study Completion Date: April 2011
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: varenicline Drug: varenicline
Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
Other Name: chantix, study drug
Placebo Comparator: placebo Drug: placebo
At the end of Pre-med week 1, subjects will receive study medication with the target quit date being the following week. Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
Other Name: sugar pill

Detailed Description:
The primary objective of the data analysis will be to measure the rate of smoking cessation in the two treatment groups. Smoking cessation will be measured weekly through a composite measure of self-reported abstinence, end expired carbon monoxide (CO) of less than C10 ppm and urine cotinine dipstick measure of < 30 ng/ml. The primary endpoint will be point prevalence at 12 weeks. The four week continuous abstinence rate for the last four weeks of the treatment phase will also be evaluated. The point prevalence abstinence rates will also be obtained. The secondary objective is to determine whether smoking cessation is associated with a worsening of cognition and psychiatric symptomology. We hypothesize that subjects who achieve abstinence in the varenicline group will not show worsening on neurocognitive and symptom measures compared to abstinence subjects in the placebo group. Lastly, we will attempt to identify any clinical or topographic markers which predict cessation.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18-64
  • Regular ten cigarette per day smoker for one year
  • Nicotine Dependency Score greater than or equal to four
  • DSM-IV Diagnosis of Schizophrenia or Schizoaffective disorder
  • Psychiatric medication regimen unchanged for at least 90 days
  • Psychiatric medication dosage unchanged for at least 30 days

Exclusion Criteria:

  • Psychiatric hospitalization in last 6 months
  • Meets criteria for current Major Depressive Disorder or has a score of greater than 10 on the Calgary Depression Scale (see withdrawal criteria)
  • Suicide or homicide ideation with a plan in the last six months
  • Life time history of suicide attempt
  • Has had a diagnosis of Schizophrenia or Schizoaffective disorder for less than three years
  • Current treatment with Bupropion SR
  • DSM-IV diagnosis of alcohol or substance dependence within last 6 months*
  • DSM-IV diagnosis of alcohol or substance abuse within three months *
  • Pregnancy or lactation in females (+HCG)
  • Use of tobacco product other than cigarettes
  • Use of nicotine replacements
  • Unstable or serious medical condition in last 6 months
  • Regular use of cimetidine (OTC or Rx) *Substance abuse/dependency exclusions do not apply to abuse of or dependence on nicotine.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00554840


Sponsors and Collaborators
University of Maryland
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Elaine Weiner, M.D. University of Maryland
  More Information

Responsible Party: Elaine Weiner, Physician, Maryland Psychiatric Research Center, Outpatient Research Program, University of Maryland
ClinicalTrials.gov Identifier: NCT00554840     History of Changes
Other Study ID Numbers: HP-00042225
First Submitted: November 6, 2007
First Posted: November 7, 2007
Results First Submitted: May 11, 2016
Results First Posted: May 15, 2017
Last Update Posted: May 17, 2017
Last Verified: May 2017

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Varenicline
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs